ES2139638T3 - 1,4-piperazinas disustituidas para el tratamiento de las enfermedades del sistema nervioso central y de las enfermedades neuroendocrinas. - Google Patents

1,4-piperazinas disustituidas para el tratamiento de las enfermedades del sistema nervioso central y de las enfermedades neuroendocrinas.

Info

Publication number
ES2139638T3
ES2139638T3 ES93401476T ES93401476T ES2139638T3 ES 2139638 T3 ES2139638 T3 ES 2139638T3 ES 93401476 T ES93401476 T ES 93401476T ES 93401476 T ES93401476 T ES 93401476T ES 2139638 T3 ES2139638 T3 ES 2139638T3
Authority
ES
Spain
Prior art keywords
diseases
piperazines
disputed
treatment
nervous system
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES93401476T
Other languages
English (en)
Inventor
Jean-Louis Peglion
Bertrand Goument
Mark Millan
Jean-Michel Rivet
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
ADIR SARL
Original Assignee
ADIR SARL
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ADIR SARL filed Critical ADIR SARL
Application granted granted Critical
Publication of ES2139638T3 publication Critical patent/ES2139638T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/26—Psychostimulants, e.g. nicotine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Diabetes (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Anesthesiology (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Compounds Containing Sulfur Atoms (AREA)
  • Furan Compounds (AREA)
  • Pyrane Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Heterocyclic Compounds That Contain Two Or More Ring Oxygen Atoms (AREA)

Abstract

NUEVAS PIPERAZINAS 1,4-DISUSTITUIDAS, UTILIZABLES COMO MEDICAMENTO Y QUE RESPONDEN A LA FORMULA (I); EN LA CUAL R, D Y -A-B BAJO FORMAS RACEMICAS Y OPTICAMENTE ACTIVAS, Y SUS SALES DE ADICION ACIDAS FISIOLOGICAMENTE TOLERABLES. ESTOS COMPUESTOS Y SUS SALES FISIOLOGICAMENTE TOLERABLES PUEDEN SER UTILIZADOS EN TERAPEUTICA.
ES93401476T 1992-06-12 1993-06-10 1,4-piperazinas disustituidas para el tratamiento de las enfermedades del sistema nervioso central y de las enfermedades neuroendocrinas. Expired - Lifetime ES2139638T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR929207065A FR2692264B1 (fr) 1992-06-12 1992-06-12 Nouvelles piperazines 1,4-disubstituees, leur procede de preparation et les compositions pharmaceutiques les contenant.

Publications (1)

Publication Number Publication Date
ES2139638T3 true ES2139638T3 (es) 2000-02-16

Family

ID=9430639

Family Applications (1)

Application Number Title Priority Date Filing Date
ES93401476T Expired - Lifetime ES2139638T3 (es) 1992-06-12 1993-06-10 1,4-piperazinas disustituidas para el tratamiento de las enfermedades del sistema nervioso central y de las enfermedades neuroendocrinas.

Country Status (13)

Country Link
US (1) US5464834A (es)
EP (1) EP0574313B1 (es)
JP (1) JP2634370B2 (es)
AT (1) ATE185345T1 (es)
AU (1) AU658512B2 (es)
CA (1) CA2098252A1 (es)
DE (1) DE69326637T2 (es)
DK (1) DK0574313T3 (es)
ES (1) ES2139638T3 (es)
FR (1) FR2692264B1 (es)
GR (1) GR3031492T3 (es)
NZ (1) NZ247854A (es)
ZA (1) ZA934143B (es)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9125900D0 (en) * 1991-12-05 1992-02-05 Wyeth John & Brother Ltd Piperazine derivatives
GB9308725D0 (en) * 1993-04-27 1993-06-09 Wyeth John & Brother Ltd Piperazine derivatives
FR2734819B1 (fr) * 1995-05-31 1997-07-04 Adir Nouveaux composes de la piperazine, de la piperidine et de la 1,2,5,6-tetrahydropyridine, leur procede de preparation et les compositions pharmaceutiques les contenant
US6156057A (en) * 1995-08-12 2000-12-05 Fox; James Allan Method for inducing hypothermia
JPH09124643A (ja) * 1995-08-14 1997-05-13 Bristol Myers Squibb Co 抗うつ作用を有する１−アリールアルキル−４−（アルコキシピリジニル）−又は４−（アルコキシピリミジニル）ピペラジン誘導体
FR2738823B1 (fr) * 1995-09-15 1997-10-31 Synthelabo Derives de 3-(omega-(4-(thieno(3,2-c)pyridin-4-yl)piperazin- 1-yl)alkyl)-3,4-dihydroquinolein-2(1h)-one,leur preparation et leur application en therapeutique
US5990114A (en) * 1996-02-28 1999-11-23 Recordati, S.A., Chemical And Pharmaceutical Company Use of 5-HT1A receptor antagonists for the treatment of urinary incontinence
US6090132A (en) * 1996-08-15 2000-07-18 Fox; James Allan Method and apparatus for inducing hypothermia
US6436940B2 (en) 1996-12-20 2002-08-20 H. Lundbeck A/S Indane or dihydroindole derivatives
DK0946538T3 (da) 1996-12-20 2003-11-03 Lundbeck & Co As H Indan- eller dihydroindole derivater
FR2761358B1 (fr) * 1997-03-27 1999-05-07 Adir Nouveaux composes de n-aryl piperidine, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
ES2128266B1 (es) * 1997-07-08 2000-01-16 Vita Invest Sa Compuestos derivados de tiofeno y benzotiofeno y utilizacion y composicion correspondientes.
AR013206A1 (es) * 1997-07-25 2000-12-13 Lundbeck & Co As H Derivados indol y 2,3-dihidroindol, composiciones farmaceuticas que contienen estos compuestos y el uso de dichos compuestos para la preparacion de un medicamento para el tratamiento de desordenes sensibles a la inhibicion de la reabsorcion de serotonina y antagonismo de receptores 5-ht1a.
AU736596B2 (en) 1997-07-25 2001-08-02 H. Lundbeck A/S Indole and 2,3-dihydroindole derivatives, their preparation and use
TW530054B (en) 1997-09-24 2003-05-01 Duphar Int Res New piperazine and piperidine compounds
FR2769312B1 (fr) * 1997-10-03 1999-12-03 Adir Nouveaux composes de l'indanol, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
US6040448A (en) 1997-10-24 2000-03-21 Neurogen Corporation Certain 1-(2-naphthyl) and 1-(2-azanaphthyl)-4-(1-phenylmethyl) piperazines, dopamine receptor subtype specific ligands
DE69829989T2 (de) * 1997-10-24 2006-02-23 Neurogen Corp., Branford 1-(2-naphthyl) und 1-(2-azanaphthyl)-4-(1-phenylmethyl)piperazine als dopamin d4 subtype liganden
US6177566B1 (en) 1998-06-30 2001-01-23 Neurogen Corporation 6-(4-arylalkylpiperazin-1-yl) benzodioxane and 6-(4-arylalkylpiperazin-1-yl) chromane derivatives: dopamine receptor subtype specific ligands
AR022303A1 (es) * 1999-01-22 2002-09-04 Lundbeck & Co As H Derivados de piperidina, tetrahidropiridina y piperazina, su preparacion y utilizacion
DE60013751T2 (de) * 1999-12-29 2005-09-29 Pfizer Products Inc., Groton Optisch aktive 3-((2-piperazinyl-phenyl)methyl)-1-(4-(trifluoromethyl)-phenyl)-2-pyrrolidinone als selektive 5-HT1D Rezeptor Antagonisten
ES2188344B1 (es) * 2000-11-29 2004-09-16 Laboratorios Vita, S.A. Compuestos derivados de benzotiofeno, su procedimiento de obtencion y utilizacion de los mismos.
US7504395B2 (en) * 2001-07-20 2009-03-17 Psychogenics, Inc. Treatment for attention-deficit hyperactivity disorder
US20060122177A1 (en) * 2004-12-07 2006-06-08 Solvay Pharmaceuticals B.V. Phenylpiperazines with a combination of affinity for dopamine-D2 receptors and serotonin reuptake sites
US7371769B2 (en) * 2004-12-07 2008-05-13 Solvay Pharmaceuticals B.V. Tetrahydropyridin-4-yl indoles with a combination of affinity for dopamine-D2 receptors and serotonin reuptake sites
US8101619B2 (en) * 2004-12-08 2012-01-24 Solvay Pharmaceuticals B.V. Phenylpiperazine derivatives with a combination of partial dopamine-D2 receptor agonism and serotonin reuptake inhibition
HRP20090015T3 (en) * 2004-12-08 2009-02-28 Solvay Pharmaceuticals B.V. Phenylpiperazine derivatives with a combination of partial dopamine-d2 receptor agonism and serotonin reuptake inhibition
FR2884251B1 (fr) * 2005-04-08 2007-07-13 Servier Lab Derives de piperazine, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
FR2909670B1 (fr) * 2006-12-12 2010-07-30 Sanofi Aventis Derive fluore de quinoleine-2(1h)-one,son procede de preparation et son utilisation comme intermediaire de synthese
PT3252057T (pt) 2009-12-04 2024-06-04 Sunovion Pharmaceuticals Inc Compostos multicíclicos e métodos de utilização dos mesmos
MX2019000982A (es) 2016-07-29 2019-07-04 Sunovion Pharmaceuticals Inc Compuestos y composiciones y usos de los mismos.
EA201990400A1 (ru) 2016-07-29 2019-07-31 Суновион Фармасьютикалз, Инк. Соединения и композиции и их применение
CN116808023A (zh) 2017-02-16 2023-09-29 桑诺维恩药品公司 治疗精神分裂症的方法
JP7191085B2 (ja) 2017-08-02 2022-12-16 サノビオン ファーマシューティカルズ インク イソクロマン化合物およびその使用
WO2019029802A1 (en) * 2017-08-09 2019-02-14 Telefonaktiebolaget Lm Ericsson (Publ) SYSTEM AND METHOD FOR SELECTING ANTENNA BEAM
MX2020008537A (es) 2018-02-16 2021-01-08 Sunovion Pharmaceuticals Inc Sales, formas cristalinas y metodos de produccion de las mismas.
CN113784755B (zh) 2019-03-14 2024-05-10 赛诺维信制药公司 异色满基化合物的盐及其结晶形式、制备方法、治疗用途和药物组合物
CA3180115A1 (en) 2020-04-14 2021-10-21 Sunovion Pharmaceuticals Inc. (s)-(4,5-dihydro-7h-thieno[2,3-c]pyran-7-yl)-n-methylmethanamine for treating neurological and psychiatric disorders
CN113896709B (zh) * 2021-11-22 2023-02-28 南京一苇医药科技有限公司 一种苯并噻吩-3-乙酸的合成方法

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2037852C3 (de) * 1970-07-30 1980-06-26 Boehringer Sohn Ingelheim Neue Piperazinderivate und Verfahren zu ihrer Herstellung
US4335126A (en) * 1977-03-10 1982-06-15 Degussa Aktiengesellschaft 1-[3-(3,4,5-Trimethoxyphenoxy)-2-hydroxy-propyl]-4-aryl-piperazine-derivatives having pharmaceutical activity
FR2515647A1 (fr) * 1981-11-03 1983-05-06 Cortial Nouvelles imines derivees de (phenyl-4 piperazinylethyl)-2 anilines, leur methode de preparation et leur application therapeutique
EP0190472B1 (en) * 1984-12-21 1989-07-12 Duphar International Research B.V New pharmaceutical compositions having anti-psychotic properties
DK93087A (da) * 1986-02-27 1987-08-28 Duphar Int Res Hidtil ukendte aryl substituerede (n-piperidinyl)methyl- og (n-piperazinyl)methylazoler med antipsykotiske egenskaber
JPH01113377A (ja) * 1987-10-23 1989-05-02 Yoshitomi Pharmaceut Ind Ltd ピペラジン化合物
GB8830312D0 (en) * 1988-12-28 1989-02-22 Lundbeck & Co As H Heterocyclic compounds
FR2670491B1 (fr) * 1990-12-14 1993-02-05 Adir Nouvelles piperazines 1,4-disubstituees, leur procede de preparation et les compositions pharmaceutiques les renfermant.
DE4127849A1 (de) * 1991-08-22 1993-02-25 Merck Patent Gmbh Benzodioxanderivate

Also Published As

Publication number Publication date
DE69326637D1 (de) 1999-11-11
AU4017893A (en) 1993-12-16
CA2098252A1 (fr) 1993-12-13
JPH06179670A (ja) 1994-06-28
GR3031492T3 (en) 2000-01-31
EP0574313A1 (fr) 1993-12-15
JP2634370B2 (ja) 1997-07-23
NZ247854A (en) 1994-09-27
ZA934143B (en) 1994-01-17
US5464834A (en) 1995-11-07
AU658512B2 (en) 1995-04-13
FR2692264A1 (fr) 1993-12-17
FR2692264B1 (fr) 1994-08-05
EP0574313B1 (fr) 1999-10-06
DE69326637T2 (de) 2000-05-18
DK0574313T3 (da) 2000-04-03
ATE185345T1 (de) 1999-10-15

Similar Documents

Publication Publication Date Title
ATE185345T1 (de) 1,4-disubstituierte piperazine zur behandlung von erkrankungen des zentralnervensystems und von nervenendokrinen erkrankungen
ATE125537T1 (de) 1,4-disubstituierte piperazine, verfahren zu deren herstellung und diese enthaltende pharmazeutische zusammenstellungen.
UA27749C2 (uk) Заміщені циклопропіламіно-1,3,5-триазини, їх оптичні ізомери, рацемічні суміші чи їх солі приєднання нетоксичних фармацевтично прийнятних кислот, що мають фармакологічну активність, спосіб їх одержання (варіанти) та фармацевтична композиція на їх основі
ATE116317T1 (de) Chinuclidinderivate.
NO870241L (no) Hypoglykemiske tiazolidindioner.
ES2102132T3 (es) Amidas de acidos carboxilicos heterociclicos sustituidos, su preparacion y su utilizacion como medicamentos.
DE3750668D1 (de) 7-[3-(Aminomethyl)-3-alkyl-1-pyrrolidinyl]chinolin-3-carbonsäure-Derivate und diese enthaltende pharmazeutische Zusammensetzungen.
NO940523D0 (no) Nye pyrazin-derivater
ATE191849T1 (de) Verwendung von (s)-(-)-alpha-ethyl-2-oxo-1- pyrrolidinacetamid zur herstellung eines medikaments zur behandlung von angst
KR890006621A (ko) 항불안제
FI953256A0 (fi) Hyperglykemian vastaisesti vaikuttava lääkeaine
ES2124861T3 (es) Derivados de aminoacidos y su utilizacion como inhibidores de la encefalinasa.
ATE151405T1 (de) (7s)-7-(2r)-2-(3-chlorophenyl)-2-hydoxyethylami o-5,6,7,8-tetrahydronaphtalen-2-yloxy essigsäure, ihre pharmazeutisch akzeptablen salze, mit beta-3-adrenergischer agonistischer aktivität und diese enthaltende pharmazeutische zusammensetzungen
ES2088567T3 (es) Empleo de derivados de la 2-iminotioazolidin-4-ona como nuevos productos activos para medicamentos.
FR2703048B1 (fr) Nouveaux composes n-benzylpiperazine, leur procede de preparation et les compositions pharmaceutiques les renfermant.
ES2084181T3 (es) Composiciones farmaceuticas para usar en el tratamiento del sida.
ATE24834T1 (de) Verwendung von beta-(1-adamantyl)-alpha, alphadimethylethylamin zur herstellung eines arzneimittels zur behandlung von otitis externa bei hunden.
ES2055440T3 (es) Derivados del acido quinurenico, su preparacion y composiciones farmaceuticas que los contienen.
GR3015212T3 (en) Ethanolaminebenzoate derivative, process for their preparation and pharmaceutical compositions containing them.
MX9405318A (es) Pirimidonas e imidazolinonas para tratamiento del choque.
ATE138805T1 (de) Substituiertes benzofuranylpiperidin als nootropikum
FI922482L (fi) Foerfarande foer framstaellning av kinolinfoerening.

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 574313

Country of ref document: ES